ABCSG R07 Rectal Cancer Registry (ABCSG R07 RCR)
ABCSG R07 Rectal Cancer Registry (RCR) - Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria
In Austria, patients with rectal cancer that has not spread to other parts of the body are typically treated with either total neoadjuvant therapy (TNT) or immunotherapy, depending on their microsatellite status (DNA repair capacity).
However, treatment can vary considerably between hospitals in Austria. These differences may include the type and duration of treatment, as well as the active ingredients used. There are currently no clear recommendations on which exact treatment is best for each specific case.
The aim of this observational study is to collect information on the different treatments used in Austria for patients with localized rectal cancer and to document the outcomes of these treatments.
Only information and samples collected as part of the patients' routine care will be used for the study. Participation in the study will not change or affect the treatment chosen by the treating physician.
Visão geral do estudo
Status
Condições
Descrição detalhada
The purpose of this observational study is to establish a registry for locally advanced rectal adenocarcinoma. This registry will document the treatment regimens of participants receiving "total neoadjuvant therapy (TNT)" as well as those with dMMR/MSI-H disease.
The ABCSG R07 Rectal Cancer Registry (RCR) study will provide real-world data that reflect the current therapeutic landscape for participants. Participants who are either treated with "total neoadjuvant therapy (TNT)" or those with dMMR/ MSI-H disease, as well as their response to the respective standard therapy, will be documented.
"Total neoadjuvant therapy (TNT)" is the preferred treatment option for locally advanced rectal adenocarcinoma; however, treatment is carried out according to a different TNT protocol at each hospital or institute.
Since the observational study does not interfere with the course of treatment, neither additional health risks nor any individual benefit from participation in the non-interventional study is to be expected.
This study is being conducted at approx. 6 study sites in Austria, and a total of about 600 participants (retrospective and prospective) will take part. The treating physician selects the treatment/therapy that she/he considers most appropriate for the participant. In the retrospective part participants with localized, non-metastatic rectal cancer treated with total neoadjuvant therapy or participants with dMMR/MSI-H status irrespective of treatment between June 2020 (or June 2005 for dMMR/MSI-H cohort,) and start of this non-interventional study will be enrolled.
In the prospective part participants with localized, non-metastatic rectal cancer treated with total neoadjuvant therapy or participants with dMMR/MSI-H status irrespective of treatment between start of this non-interventional study and three years thereafter will be enrolled.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Miriam Muehlburger, MSc
- Número de telefone: +43 1 4089230
- E-mail: miriam.muehlburger@abcsg.at
Locais de estudo
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Áustria, 5020
- LKH Salzburg-PMU, Univ. Klinik f. Innere Med III
-
Contato:
- Lukas Weiss, MD, Prof.
- Número de telefone: 25804 +4357255
- E-mail: lu.weiss@salk.at
-
Investigador principal:
- Lukas Weiss, MD, Prof.
-
-
Upper Austria
-
Linz, Upper Austria, Áustria, 4020
- Kepler Universitätsklinikum Linz
-
Contato:
- Gudrun Piringer, MD, MSc
- Número de telefone: +435768082
- E-mail: gudrun.piringer@kepleruniklinikum.at
-
Investigador principal:
- Gudrun Piringer, MD, MSc
-
Linz, Upper Austria, Áustria, 4010
- Ordensklinikum Linz - BHS
-
Contato:
- Holger Rumpold, MD, Head
- Número de telefone: 4230 +43-732-7677
- E-mail: holger.rumpold@bhs.at
-
Investigador principal:
- Holger Rumpold, MD, Head
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Female and male participants with age >= 18 years
- Signed informed consent obtained prior to registration of the participant.
- Localized rectal cancer treated with TNT or localized, non-metastatic dMMR/MSI-H rectal cancer, irrespective of treatment
Exclusion Criteria:
- Distant metastases at primary diagnosis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Retrospective part
Participants treated between June 2020 and study start.
For dMMR/MSI-H cohort: treated between June 2005 until study start
|
|
Prospective part
Participants treated between study start and three years after study start
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment Responses (clinical standard therapy)
Prazo: At the time of surgery
|
Recording of treatment responses according to clinical standard therapy.
|
At the time of surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of different TNT concepts used
Prazo: From therapy start to Surgery
|
Treatment details
|
From therapy start to Surgery
|
|
Proportion of participants using immunotherapy
Prazo: From therapy start to Surgery
|
From therapy start to Surgery
|
|
|
Proportion of participants using watch & wait therapy
Prazo: At surgery visit
|
At surgery visit
|
|
|
Proportion of the surgical techniques used
Prazo: At surgery
|
At surgery
|
|
|
Proportion of locoregional recurrences
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Proportion of the participants with distant metastases
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Event-free survival (EFS)
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
EFS includes locoregional event, distant metastasis and death
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
TME-free survival in watch & wait group
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Overall survival (OS)
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Locoregional event-free survival (LREFS)
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
locoregional progression, recurrence, regrowth or death
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
Distant metastasis-free survival (DMFS)
Prazo: From therapy start until 3 years from re-staging or end of primary treatment
|
From therapy start until 3 years from re-staging or end of primary treatment
|
|
|
Charlson Comorbidity Index (CCI) Score prior to any treatment start
Prazo: Baseline
|
Baseline
|
|
|
ECOG performance status at diagnosis
Prazo: Diagnosis
|
Diagnosis
|
|
|
Proportion of resection rates
Prazo: Surgery
|
Surgery
|
|
|
Treatment adherence
Prazo: From therapy start until surgery
|
From therapy start until surgery
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Falk Roeder, Prof, MD, Paracelsius Medical University Salzburg
- Cadeira de estudo: Gudrun Piringer, MD, MSc, Johannes Kepler University Linz
- Cadeira de estudo: Lukas Weiss, Prof, MD, Paracelsius Medical University Salzburg
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias por local
- Doenças Intestinais
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Neoplasias Colorretais
- Neoplasias Intestinais
- Doenças retais
- Neoplasias Glandulares e Epiteliais
- Carcinoma
- Neoplasias
- Neoplasias retais
- Adenocarcinoma
- Síndrome do turco
Outros números de identificação do estudo
- ABCSG R07
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Key-coded personal information from this study may also be used for future ((non-)commercial, (inter-)national) scientific research projects & statistics, provided the respective project is conducted in compliance with accepted standards of ethical principles; the responsible researcher(s)/statistician(s) has/have no legal means to de-identify any key-coded personal information.
Data will be shared with other collaborating academic groups/people & companies who work with the Sponsors, including but not limited to ECs, ABCSG (holder of clin. database) and will be used for study purposes mentioned in protocol & future scientific research projects, if agreed by the participant.
Any data transfer will comply with respective applicable data law/regulations. The use of data must be defined in advance in a project description & SAP, approved by ABCSG Board/Committee and will be transferred acc. with resp. Data Transfer Agreement.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .